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We have previously shown that two tumor necrosis fac-
tor (TNF) receptors (TNFR) exhibit antagonistic func-
tions during neurodegenerative processes in vivo with
TNFR1 aggravating and TNFR2 reducing neuronal cell
loss, respectively. To elucidate the neuroprotective sig-
naling pathways of TNFR2, we investigated glutamate-
induced excitotoxicity in primary cortical neurons. TNF-
expressing neurons from TNF-transgenic mice were
found to be strongly protected from glutamate-induced
apoptosis. Neurons from wild type and TNFR1/ mice
prestimulated with TNF or agonistic TNFR2-specific an-
tibodies were also resistant to excitotoxicity, whereas
TNFR2/ neurons died upon glutamate and/or TNF ex-
posures. Both protein kinase B/Akt and nuclear factor-B
(NF-B) activation were apparent upon TNF treatment.
Both TNFR1 and TNFR2 induced the NF-B pathway, yet
with distinguishable kinetics and upstream activating
components, TNFR1 only induced transient NF-B activa-
tion, whereas TNFR2 facilitated long term phosphatidyli-
nositol 3-kinase-dependent NF-B activation strictly. Glu-
tamate-induced triggering of the ionotropic N-methyl-D-
aspartate receptor was required for the enhanced and
persistent phosphatidylinositol 3-kinase-dependent NF-B
activation by TNFR2, indicating a positive cooperation
of TNF and neurotransmitter-induced signal pathways.
TNFR2-induced persistent NF-B activity was essential for
neuronal survival. Thus, the duration of NF-B activation is
a critical determinant for sensitivity toward excitotoxic
stress and is dependent on a differential upstream signal
pathway usage of the two TNFRs.
Tumor necrosis factor (TNF)1 is a prominent proinflamma-
tory mediator that has been causally associated with the patho-
physiology of several acute and chronic diseases, in particular
rheumatoid arthritis and Morbus Crohn (1, 2). Up-regulated
TNF expression has also been found in various neurodegenera-
tive diseases such as cerebral malaria, AIDS dementia, Alzhei-
mer’s disease, multiple sclerosis, and stroke, suggesting a po-
tential pathogenic role of TNF in these diseases as well (3–7).
The membrane-expressed form of TNF signals through both
TNF receptors (TNFR1 and TNFR2), whereas soluble TNF
proteolytically cleaved from the membrane form acts mainly
via TNFR1 (8). Signal pathways initiated from the death do-
main-containing TNFR1, leading to both proapoptotic and anti-
apoptotic cellular responses, have been studied in great detail
(9). In contrast, there is less information regarding the molec-
ular mechanisms surrounding signal pathways and cellular
responses solely initiated via TNFR2 because of concomitant
TNFR1 signals in normal situations. The evaluation of the
physiological role of TNFR2 by large depends on data obtained
from TNFR1/ mice.
We have recently investigated the role of TNF and its recep-
tors in retinal ischemia and unraveled an antagonistic function
of TNFR1 and TNFR2. TNFR2 exerts neuroprotection in a
phosphatidylinositol 3-kinase (PI3K) dependent manner,
which is counterbalanced by the neurodegenerative action of
TNFR1 (10). TNFR1 has also been associated with the cell
death of hippocampal neurons responding to TNF (11), whereas
inhibition of TNFR2 expression by the use of antisense oligo-
nucleotides sensitized neuronal-like cells toward apoptosis
(12). To elucidate the neuroprotective signal pathways emanat-
ing from TNFR2, we have established an in vitro model of
apoptosis induction of primary cortical neurons by glutamate-
triggered excitotoxicity to study mechanisms controlling apo-
ptosis sensitivity of neurons within wild type (C57BL/6) and
TNF transgenic TNFR1/ and TNFR2/ mice. Our data
reveal, for the first time, differential activation kinetics of
NF-B and differential usage of upstream signaling compo-
nents by TNFR1 and TNFR2. TNFR2, but not TNFR1, induces
persistent NF-B activation via a signaling pathway involving
PI3K and PKB/Akt, which is strongly enhanced by N-methyl-
D-aspartate receptor co-stimulation.
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Generation of Transgenic Mice with Brain-specific TNF Expression—
Transgenic mice were developed by pronuclear injection in general as
previously described (13). A construct consisting of the murine NMDAR
subunit 2B (NR2B) promoter and the first three exons of the 5-un-
translated region (UTR) of the NR2B gene was fused with the NarI site
of the first exon of the murine TNF gene with the replaced 3-UTR (3
part of exon 4 of the TNF gene) by the 3-UTR of the human -globin
gene (14). Four mouse lines were investigated and showed similar TNF
expression patterns differing only in the level of and duration of expres-
sion. The expression pattern was verified by in situ hybridization as
described previously (15). The pBSII-SK plasmid containing a cDNA of
the murine TNF gene was digested either with PstI or EcoRI for
synthesis of a 35S-labeled sense or antisense probe using T3 or T7 RNA
polymerase.
Primary Cortical Cell Culture—Cortical cultures were prepared as
follows. Embryonic brains were extracted (embryonic day 14), the me-
ninges were removed, and the cortices were dissected immediately.
Neurons were recovered by mechanical dissociation. Cells were plated
at a density of 1  105 cells/cm2 (96- or 6-well plates) or 2.5  104
cells/cm2 (24-well plates) on poly-L-lysine (Sigma) coated plates. Neu-
robasal medium with B27 supplement (Invitrogen) and 0.5 mM gluta-
mine with a final concentration of 0.1 mg/ml gentamycin (Invitrogen)
and 2.5 g/ml amphotericin B (Sigma) was used as culture medium. On
the second day in vitro, cells were treated with 10 M cytosine arabi-
noside for 48 h to inhibit non-neuronal cell growth. Subsequently, the
medium was completely exchanged, and every third day afterward,
fresh medium was added.
Cells were either stimulated with increasing concentrations of glu-
tamate for 1 h (Figs. 2B, 3, A and C, and 8C) or for 24 h with the
indicated concentrations of TNF (Figs. 3B and 8, A and B) or TNFR
agonistic antibodies (Fig. 4, A–C) followed by a 1-h stimulation of 250
M glutamate (Sigma) and the determination of the cell viability 24 h
later. When indicated, cells were incubated prior to the glutamate
stimulus with an inhibitor of PI3K (LY294002 (25 M), Calbiochem, or
wortmannin (100 nm), Sigma), NMDAR (MK801 (10 M), Tocris),
caspases (Z-VAD-fmk (20 M), BACHEM), or NF-B (MG-132 (20 M),
Calbiochem; geldanamycin (0.5 M), Calbiochem; or BAY11-7082 (20
M), Alexis Biochemicals). To determine the kinetics of cell death in-
duction, primary cortical neurons were incubated for 1 h with 250 and
500 M glutamate and cell viability was assessed directly after the
stimulus (1-h) or 1 (2-h), 3 (4-h), 5 (6-h), and 23 (24-h total
incubation time) h later (Fig. 2A). Agonistic antibodies (2 g/l; HyCult
Biotechnology) were cross-linked by a mouse anti-rat antibody (2 g/l;
Jackson ImmunoResearch, Dianova, Hamburg, Germany) to obtain
optimum triggering of the TNFRs.
Determination of Cell Viability—Cell viability was determined by the
colorimetic MTT (3-(4,5-dimethylthiazol-2-yl-)2,5-diphenyltetrazolium
bromide) assay as described previously (16). Primary cortical neurons
were grown in 96-well microtiter plates at a density of 6 104 cells/well
and stimulated as indicated. 10 l of an MTT solution (1.25 mg/ml) was
added to each well. After a 1-h incubation, cells were lysed by adding
150 l of isopropyl-HCl solution (600 l of HCl/100 ml isopropyl alcohol)
for 15 min. The absorbance of each well was determined with an
automated ELISA reader (Bio-Rad) at 590 nm with a background cor-
rection at 620 nm.
Western Blot—Cytosolic extracts from primary cortical neurons (2 
106) were prepared by washing twice with ice-cold phosphate-buffered
saline (PBS) followed by the addition of 0.4 ml of the cell lysis buffer (10
mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT, and 1 mM phenylmethylsulfonyl fluoride). Lysates were incubated
on ice for 20 min. 25 l of 10% Nonidet P-40 was added for 2 min, and
nuclei were collected by centrifugation. The supernatants were boiled
for 5 min in Laemmli’s sample buffer (2% SDS, 5% DTT), and 50 g of
protein was separated by SDS-polyacrylamide gel electrophoresis. After
transfer to a nitrocellulose membrane (Hybond ECL, Amersham Bio-
sciences), proteins were detected with a specific primary and a horse-
radish peroxidase-conjugated secondary antibody using enhanced
chemiluminescence according to the manufacturer’s instructions
(LuminGlo, New England Biolabs).
Primary antibodies included were a rabbit polyclonal antibody spe-
cific for the phospho-PKB/Akt serine 473 residue (1:1000; Cell Signal-
ing), total PKB/Akt (1:1000; Cell Signaling), IB (1:500; Santa Cruz
Biotechnology), phospho-IB (1:1000; Cell Signaling), TNF (1:1000;
BIOSOURCE), and glutamate receptor 1 (1:300; Chemicon).
Immunocytochemistry and Immunohistochemistry—Cells were fixed
with 4% paraformaldehyde in PBS, pH 7.4, for 20 min at room temper-
ature, permeabilized with 0.1% Triton X-100/PBS for 5 min, and
blocked with 5% goat serum in PBS. Overnight incubation with a
polyclonal rabbit anti-p65 antibody (1:500; Oncogene) or rabbit anti-
TNF antibody (1:1000, Santa Cruz Biotechnology) at 4 °C was followed
by a 1-h incubation with a fluorescent-labeled Alexa 546 or 488 anti-
rabbit antibody (1:1000; Molecular Probes) at room temperature. Neu-
rons were labeled with a monoclonal neuronal-specific mouse anti-
unique--tubulin antibody (1:2000; Babco) for 1.5 h at room
temperature and a Alexa 488 or 546 anti-mouse antibody (1:1000).
Glia cells were detected using a monoclonal mouse anti-glial fibril-
lary acidic protein antibody (1:2000; Sigma) and a secondary Alexa
546-labeled anti-mouse antibody (1:1000). The glia cell content resulted
in 0.5%.
Determination of apoptosis induction was assessed after fixation of
stimulated (1 h 250 M glutamate) and unstimulated cells by incubation
with an annexin V-specific fluorescein isothiocyanate-conjugated anti-
body (1:20; BD Biosciences) for 1 h at room temperature followed by a
1-h incubation with DAPI (0.1 g/ml) for nuclear staining,
For immunohistochemical staining, paraffin-embedded sections were
permeabilized with 0.02% H2O2-methanol for 30 min and blocked with
10% fetal calf serum for 20 min. Sections then were incubated with
specific antibodies (rabbit-anti-TNF (Genzyme) at 1:1000; rat-anti-
mac3 (BD Biosciences) at 1:200; and rat-anti-CD45 (BD Biosciences) at
1:100 in 0.1% bovine serum albumin/Tris-buffered saline) at 4 °C over-
night, washed, incubated with a biotin-labeled anti-rabbit IgG or anti-
rat-IgG (Vector Laboratories at 1:200 in 2.5% bovine serum albumin/
Tris-buffered saline), and stained with avidin-diaminobenzidine
(Sigma) according to the manufacturer’s protocol.
Electrophoretic Mobility Shift Assay (EMSA)—For preparation of
nuclear extracts, 2  106 primary cortical neurons were washed once
with cold PBS, resuspended in 0.4 ml of lysis buffer (10 mM HEPES, pH
7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride) and then incubated on ice for 20 min.
Subsequently, 25 l of 10% Nonidet P-40 was added for 2 min, and
nuclei were collected by centrifugation and resuspended in 20 mM
HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
and 1 mM phenylmethylsulfonyl fluoride, shaken for 20 min, and then
centrifuged. The supernatant containing nuclear proteins was used for
EMSA. The NF-B consensus oligonucleotide (5-ATCAGGGACTTTC-
CGCTGGGGACTTTCCG-3) was 5-labeled with [-32P]ATP using
polynucleotide kinase. Binding reaction was performed by incubating
10 g of nuclear protein extracts with 4 g of poly(dI-dC) in a 20-l
reaction mixture containing 5 mM MgCl2, 50 mM KCl, 5 mM HEPES, pH
7.8, 0.2 mM EDTA, 5 mM DTT, and 10% glycerol. The double-stranded
oligonucleotide probe (50,000 cpm/l) was added for 20 min at room
temperature. Binding specificity was determined by competition with
excess (100 ng) unlabeled NF-B oligonucleotide. DNA/protein com-
plexes were analyzed on non-denaturing 6% polyacrylamide gels and
visualized by PhosphorImaging. For supershift assays, nuclear extracts
were preincubated with p65, p50, or cRel antibodies (1 g/ml; Santa
Cruz Biotechnology) for 30 min at room temperature.
RESULTS
Generation and Analyses of NR2B/TNF Transgenic Mice—
Previous transgenic mouse models resolving the role of TNF in
the brain were designed to cause a widespread and often high
level of TNF expression, which was typically associated with
various pathologies (17–20). To avoid unconditional TNF ex-
pression, we have employed the promoter of the murine NMDA
receptor subunit NR2B gene to generate mice with a strictly
regional and rather moderate neuronal TNF expression. The
endogenous expression of NR2B subunit is restricted to fore-
brain regions and mainly expressed in cortical and hippocam-
pal regions of the brain (21, 22). To enforce this restricted
expression pattern of TNF in transgenic mice, the 5-UTR of
the NR2B gene, which was shown to influence the expression
pattern, was also included in the construct (Fig. 1A) (20, 23).
NR2B-directed TNF transgene expression was verified by in
situ hybridization (Fig. 1B), Western blot analyses in embry-
onic day 14 and postnatal day 14 tissues (Fig. 1C), immunola-
beling of primary neuronal cells (Fig. 1, D and E), and immu-
nostaining in paraffin sections (Fig. 1F, upper panel).
Interestingly, among the four generated mouse lines, no in-
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flammatory responses such as infiltration or spontaneous de-
myelinating lesions were observed as reported from other
mouse models with ubiquitous and high level of TNF expres-
sion (17–20). Only in areas of strongest TNF expression (i.e.
hippocampus and cortex), ramified microglial cells positive for
CD45 or mac3, considered as activation markers, could be
detected (Fig. 1E, middle and lower panels). The data show
that TNF transgene expression is in concordance with the
expected pattern of the NR2B gene (22, 23). Moreover, immu-
nohistochemical detection of TNF protein and microglial acti-
vation in tissue sections of transgenic but not of non-transgenic
littermates indicates functional in vivo expression of the trans-
gene. In addition, bioactive TNF could be detected on the cell
membrane (Fig. 1, D and E) and in the supernatant of culti-
vated NR2B/TNF transgenic neurons (6  106 cells release 1
ng of soluble TNF in 24 h) but not in that of neurons from
control littermates as determined by a standard bioassay (data
not shown) (24, 25). Glutamate treatment had no effect on the
FIG. 1. Generation of NR2B/TNF transgenic mouse lines. A, schematic depiction of the transgene construct. The promoter and 5-UTR
of the NMDA receptor subunit NR2B gene (exons 1–3 in green boxes) was fused to the NarI site of the murine TNF gene (red boxes) in exon
1, thus replacing part of its 5-UTR. The 3-UTR of the murine TNF gene was replaced by the human -globin gene (yellow box) (14) for
stabilizing the transgenic message, resulting in a 4.9-kb DNA fragment, which was used for pronuclear injection. B, in situ hybridization. 10
m of semi-thin cryostat midsagittal sections were hybridized with a 35S-labeled TNF-antisense probe to detect TNF expression in the brain
of transgenic mice (three months of age). In contrast to non-transgenic controls, transgene expression could be detected in forebrain regions,
mainly in the cortex and hippocampus resembling the expression pattern of the NR2B gene. C, Western blot. Detection of TNF expression in
embryonic (embryonic day 14) and postnatal cortical tissue (postnatal day 14) of NR2B/TNF transgenic (tg) animals in comparison to
non-transgenic (ntg) control. D, immunocytochemistry. TNF expression was detected by a rabbit anti-TNF antibody (red fluorescence, Alexa
546) in in vitro cultivated cortical neurons by video microscopy. Left picture shows TNF expression alone, and the right picture shows TNF
expression merged with III-tubulin staining (green fluorescence, Alexa 488) to mark neuronal cell bodies. E, confocal section of TNF-stained
(red fluorescence, Alexa 546) and tubulin-stained (green fluorescence, Alexa 488) cortical neurons to verify membrane expression of TNF. F,
immunohistochemistry. 1-month-old tg and ntg cortex was stained for TNF in the upper panel. Staining for CD45 (middle panel) and mac3
(lower panel) indicates activated microglia in TNF transgenic cortices.
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NR2B promoter activity as determined by semi-quantitative
reverse transcription-PCR of NR2B mRNA levels in wild type
neurons (data not shown).
TNF/TNFR2-mediated Signaling Protects Primary Cortical
Neurons from Glutamate-induced Cell Death—Exposure of
wild type murine primary cortical neurons to neurotoxic doses
of glutamate lead to a time- and dose-dependent induction of
cell death (Fig. 2, A and B), which was inhibited by the caspase
inhibitor, Z-VAD-fmk (Fig. 2B). Furthermore, nuclear fragmen-
tation, annexin V staining (Fig. 2C), and inhibition of neuronal
cell death by MK801 (Fig. 3A), an inhibitor of the NMDA
receptor, is indicative of NMDAR-mediated excitotoxic induc-
tion of apoptosis, which is in accordance with previous studies
(26). Primary cortical neurons from NR2B/TNF transgenic
animals, in contrast to wild type and TNFR1- (TNFR1/) and
TNFR2-deficient (TNFR2/) cells, were found to be almost
completely resistant to glutamate-triggered excitotoxicity (Fig.
3A). To mimic the conditions of continuous TNF expression of
TNF transgenic animals, wild type and TNFR/ neuronal
cells were pretreated for 24 h with TNF. Under these condi-
tions, resistance toward glutamate-induced apoptosis could be
induced in wild type and, to an even greater extent, in
TNFR1/ neuronal cells (Fig. 3B). By contrast, TNFR2/
neurons were not only more susceptible to glutamate-induced
cell death but also died upon TNF exposure (Fig. 3B). TNF
stimulation of neuronal cultures simultaneously or subsequent
to glutamate addition was found to be non-protective (data not
shown). These data indicate that the resistance of primary
cortical neurons toward an excitotoxic stimulus requires a pre-
ceding TNF signal via TNFR2. Studying ischemia reperfusion-
induced damage of the retina of TNFR1/ mice, we have
recently shown that the locally applied PI3K inhibitor,
LY294002, aggravated neuronal degeneration (10). Therefore,
we have investigated the role of PI3K in the glutamate-induced
in vitro excitotoxicity model. The glutamate resistance of
NR2B/TNF transgenic cortical neurons (Fig. 3C) and TNF-
pretreated neurons of wild type or TNFR1/ mice (Fig. 3B)
was completely abolished by LY294002. Of note, although we
found that protection of wild type and TNFR1/ neurons
required in vitro preincubation with TNF, the addition of the
PI3K inhibitor as little as 30 min before the excitotoxic stimu-
lus fully prevented the TNF-dependent survival of neurons
(Fig. 3B). This finding indicates that in order to accumulate a
protective TNF response, the TNFR2-mediated activation of a
FIG. 2. Glutamate-induced apopto-
sis in primary cortical wild type cul-
tures. A, 250 () and 500 (f) M gluta-
mate induces neuronal death in a time-
dependent manner. Cell viability was
assessed at the indicated times after a 1-h
glutamate stimulus. B, dose-dependent
neuronal cell death in the absence ()
and presence (f) of the caspase inhibitor
Z-VAD (20 M). Cell death in A and B was
assessed by MTT assay (n  3) as de-
scribed under “Experimental Proce-
dures.” C, immunocytochemistry. DAPI
(blue fluorescence) and annexin V (green
fluorescence) staining of in vitro culti-
vated primary cortical neurons. Upper
panel depicts unstimulated cells. Lower
panel depicts neurons after treatment for
1 h with 250 M glutamate. Glutamate-
treated neurons exhibit membrane-local-
ized punctated annexin V staining and
nuclear fragmentation (arrows).
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PI3K pathway has to occur within a narrow time span before
the excitotoxic insult.
Further evidence for distinct proapoptotic and anti-apoptotic
pathways emanating from TNFR1 and TNFR2, respectively,
was obtained by the use of TNFR subtype-specific agonistic
antibodies (27), allowing selective stimulation of either recep-
tor in wild type neurons. TNFR specificity of the antibodies was
verified by analyzing reactivity on TNFR1/ and TNFR2/
neurons (data not shown). The TNFR1-specific agonist alone
elicited neuronal cell death in wild type neurons in a dose-de-
pendent manner and did not protect from glutamate-induced
apoptosis (Fig. 4A). Conversely, selective stimulation of TNFR2
had no cytotoxic effect but instead led to an inhibition of neu-
rotransmitter-triggered excitotoxicity (Fig. 4B). Again, the
blocking of PI3K by LY294002 reverted the TNFR2-mediated
protection (Fig. 4B), whereas the TNFR1-mediated cell death
was not affected by the PI3K inhibitor (Fig. 4A). The critical
involvement of PI3K signaling was confirmed by usage of wort-
mannin after selective TNFR2 stimulation (Fig. 4C) or TNF
preincubation (data not shown).
NMDAR Signaling Enhances TNFR2-induced PKB/Akt Ac-
tivation—PKB/Akt is considered to be a prominent and ubiq-
uitous downstream target protein of PI3K (28). Because of the
TNF- and PI3K-dependent protection of cortical neurons from
glutamate-induced apoptosis, we investigated PKB/Akt activ-
ity during excitotoxic stimulation of untreated and TNF-pre-
treated wild type, TNFR1/, and TNFR2/ mice as well as
that of NR2B/TNF transgenic mice. Western blot analyses
were performed with protein lysates from cortical neurons
treated with TNF and/or glutamate in the presence or absence
of a specific NMDAR blocker (MK801) or a selective PI3K
inhibitor (LY294002). Intense and persistent PKB/Akt phos-
phorylation was detected in both TNFR1/ and wild type
neurons after TNF and glutamate co-stimulation (Fig. 5A,
lanes 4, 8, and 12). This was partially inhibited by LY294002 in
wild type cells and completely abolished in TNFR1/ cells
(Fig. 5A, lanes 6, 10, and 14). In TNFR2/ neurons, only a
weak transient PKB/Akt activation was detected upon gluta-
mate and TNF treatment (Fig. 5A, lanes 4, 8, and 12). These
data show that the TNF-induced persistent PKB/Akt phospho-
rylation is TNFR2-mediated and PI3K-dependent. Moreover,
we reveal to date an unrecognized strong enhancement of this
signal pathway by the glutamate-activated NMDAR.
In contrast to wild type, TNFR1/, and TNFR2/ neu-
rons, substantial levels of phospho-PKB/Akt were detected in
NR2B/TNF transgenic neurons without in vitro TNF treat-
ment (Fig. 5B, lane 1), which is in accordance with endogenous
TNF expression in these neurons. As expected from the above
experiments, PKB/Akt phosphorylation was PI3K-dependent
at all of the time points analyzed (Fig. 5B, lanes 4, 7, 10,
and 12).
NMDAR Signaling Increases TNFR2-induced NF-B Activa-
tion—NF-B activation in primary cortical neurons was deter-
mined by immunofluorescence microscopy of nuclear translo-
cated p65 (Fig. 6A) as well as by the EMSA (Fig. 6, E and F).
The lone TNF treatment of TNFR1/ or TNFR2/ neurons
revealed characteristic differences in NF-B activation (Fig.
6B). Nuclear NF-B translocation after stimulation of TNFR1
reached a maximum between 20 and 40 min (Fig. 6B, white
bars), whereas TNFR2-mediated NF-B translocation in-
creased gradually, peaked after 4 h of stimulation, and was still
discernable after 24 h (Fig. 6B, black bars). Wild type neurons,
which express both TNFRs, exhibited intermediate transloca-
tion kinetics (Fig. 6B, gray bars). Upon glutamate stimulation
FIG. 3. TNF mediates anti-apoptotic
signals via TNFR2. A, differences in
sensitivity for glutamate-induced excito-
toxicity of primary cortical neurons from
different mouse lines in the absence (open
symbols) or presence (filled symbols) of
the NMDAR blocker MK801 ( and f,
wild type (WT); ‚ and Œ, NR2B/TNF; E
and , TNFR1/ (R1/);  and ,
TNFR2/ (R2/)). B, TNF dose-
dependent protection of primary neuronal
cultures after exposure to excitotoxic con-
centrations of glutamate (1 h, 250 M) in
the absence (open symbols) or presence
(filled symbols) of the LY294002 ( and
f, WT; E and , R1/;  and ,
R2/; ‚ and Œ, WT without glutamate
to detect possible toxicity of the inhibitor
(performed for all of the cell lines shown
as an example for wild type cells)). C, the
PI3K inhibitor, LY249002, can revert
neuroprotection in NR2B/TNF trans-
genic neurons (‚ and Œ, NR2B/TNF; 
and f, WT; open symbols, without inhib-
itor; filled symbols, with LY249002). Cell
death in A, B, and C was assessed by MTT
assay (n  3) as described under “Exper-
imental Procedures.”
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FIG. 5. Western blot analysis of Akt
in protein lysates from primary cor-
tical cultures of different mouse lines
treated with glutamate and inhibi-
tors of NMDAR and/or PI3K. A, detec-
tion of phosphorylated PKB/Akt (serine
473) and total PKB/Akt protein (in order
to control equal protein loading) in wild
type (WT), TNFR1/ (R1/), and
TNFR2/ (R2/) neurons after TNF,
MK801, or LY294002 preincubation and
glutamate stimulation as indicated B. de-
tection of PKB/Akt and its phosphoryl-
ated residue (serine 473) in NR2B/TNF
transgenic neurons after MK801 or
LY294002 preincubation and glutamate
stimulation as indicated.
FIG. 4. Agonistic TNFR antibodies mimic TNF preincubation in primary cortical wild type neurons. A, dose-dependent toxicity of
primary neuronal cultures by agonistic TNFR1-monoclonal antibody after exposure to excitotoxic concentrations of glutamate (1 h, 250 M) in the
absence (open symbols) or presence (filled symbols) of LY294002 ( and f, wild type (WT); ‚ and Œ, WT without glutamate to detect possible
toxicity of the inhibitor). B and C, dose-dependent neuroprotection of primary neuronal cultures by agonistic TNFR2-monoclonal antibody after
exposure to excitotoxic concentrations of glutamate (1 h, 250 M) in the absence (open symbols) or presence (filled symbols) of LY294002 (B) or
wortmannin (C) ( and f, WT; ‚ and Œ, WT without glutamate to detect possible toxicity of the inhibitor). Cell death in A, B, and C was assessed
by MTT assay (n  3) as described under “Experimental Procedures.”
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of TNF-pretreated (24 h) cultures, a strong enhancement of the
residual low level NF-B activity could be identified by nuclear
translocation (Fig. 6C) and EMSA (Fig. 6E) in wild type and in
TNFR1/ neurons, whereas TNFR2/ neurons showed no
enhancement of NF-B activation by glutamate (Fig. 6, C,
white bars, and E, lanes 2, 4, and 8). Of note, upon glutamate
treatment alone, no NF-B activation was discerned (Fig. 6, C
and E, lanes 3, 7, and 11). In TNF-pretreated wild type neu-
rons, weak NF-B activity (Fig. 6, B, gray bars, and E, lane 2)
strongly increased after glutamate stimulation and persisted
at elevated levels for at least 4 h (Fig. 6, C, gray bars, and E,
lanes 4, 8, and 12). In these cells, the enhancement was
strongly reduced by MK801 and LY294002 when assessed dur-
ing the first 2 h (Fig. 6, C, gray bars, and E, lanes 5, 6, 9, and
10) and NF-B activity was no longer discernable by EMSA in
LY294002-treated cultures at 4 h after glutamate stimulation
(Fig. 6E, lane 14). These results indicate an important contri-
bution of a TNFR2-dependent pathway for NF-B activation in
wild type neurons, in particular at later time points of gluta-
mate exposure. TNFR1/ neurons had comparable activation
kinetics to wild type neurons with one remarkable difference.
At every time point measured, NF-B activation was com-
pletely inhibited by LY294002 (Fig. 6, C, black bars, and E,
lanes 6, 10, and 14), clearly suggesting that, in cortical neuro-
nal cells, TNFR2-mediated NF-B activation is PI3K-depend-
ent. Moreover, the virtually complete blocking of the enhance-
ment of the TNF-induced NF-B response by MK801 discloses
the essential role of NMDAR co-activation in wild type and
TNFR1/ neurons (Fig. 6E, lanes 5, 9, and 13). By contrast,
PI3K dependence of neuronal TNFR1-mediated NF-B activa-
tion was apparently less stringent. For example, although the
NF-B response of TNF-pretreated TNFR2/ neurons was
partially LY 294002-sensitive 1 h post-glutamate treatment, it
remained completely unaffected by LY294002 at 2 h (Fig. 6, C
and E, lanes 4 versus 6 and 8 versus 10). Of greater relevance,
EMSA confirmed that TNFR1-mediated NF-B activation does
not persist and lacks enhancement through NMDAR activa-
tion. Similar to PKB/Akt activity, NR2B/TNF transgenic neu-
rons displayed basal NF-B activity because of the constitutive
expression of TNF (Fig. 6, D and F, lane 1). Additional gluta-
mate stimulation enhanced nuclear NF-B translocation (Fig.
6D) and its activation (Fig. 6F, lanes 2, 5, and 8), which could
be partially reduced by MK801 (Fig. 6, D and F, lanes 3, 6, and
9) and fully abrogated by LY294002 2 and 4 h after glutamate
stimulation (Fig. 6, D and F, lanes 7 and 10). Further, incuba-
tion of NR2B/TNF transgenic neurons with LY294002 inhib-
ited endogenous NF-B activation as well (Fig. 6F, lane 12),
indicating that chronic TNF expression in these cells appar-
ently imposes a bias on TNF signaling toward TNFR2 path-
ways. Supershift analysis using antibodies against p65, p50,
and cRel identified p50 and p65 as the predominant NF-B
subunits (Fig. 6G) in all of the mouse strains tested. Although
the latter experiment is in accordance with the view that both
TNFR1 and TNFR2 use the canonical NF-B pathway (9), the
differential kinetics of activation and sensitivity toward PI3K
inhibitors in primary cortical neurons indicate distinct up-
stream signal pathway usage of the two TNFRs. TNFR1-medi-
ated induction of NF-B is transient, whereas TNFR2 can
induce a more lasting NF-B activation. The latter is strictly
PI3K-dependent and enhanced by co-stimulation of the iono-
tropic NMDA receptor. In contrast, the TNFR1-mediated
NF-B activation is less dependent on PI3K and not enhanced
by NMDA receptor activation.
TNFR2-dependent Induction of IB Degradation Is Sensitive
to PI3K Inhibition—To assess the molecular level of PI3K/Akt-
mediated NF-B activation, IB phosphorylation and subse-
quent degradation were analyzed in NR2B/TNF transgenic or
TNF-pretreated wild type, TNFR1/, and TNFR2/ neu-
rons. In TNFR1/ cells, the phosphorylation and depletion of
IB occurred earlier and was stronger as compared with wild
type cells (Fig. 7A, lanes 3–7). LY294002 sensitivity of IB
phosphorylation and degradation was more pronounced in
TNFR1/ neurons as compared with wild type neurons (Fig.
7A, lanes 10–14). Consistent with the shorter NF-B activation
kinetics in TNFR2/ neurons, only transient IB phosphoryl-
ation and degradation were observed in these cells (Fig. 7A,
lanes 3–7) that were largely LY204002-insensitive (Fig. 7A,
lanes 10–14). NR2B/TNF transgenic neurons exhibited contin-
uous (Fig. 7B, lanes 2–6) LY294002-sensitive (Fig. 7B, lanes
8–12) IB phosphorylation and depletion due to the continuous
expression of TNF. This finding is consistent with the basal
activation of NF-B observed in these cells (Fig. 6, C and E).
LY294002 treatment significantly raised IB levels and de-
creased the proportion of phosphorylated IB in NR2B/TNF
transgenic neurons (Fig. 7B, lane 7), indicating permanent
PI3K-dependent signaling through TNFR2. The transient
LY249002-insensitive reduction in IB levels observed at
around 60 min (Fig. 7B, lane 11) probably reflects concomitant
TNFR1 activity and/or other TNFR2-independent signals. To
verify specific proteasomal degradation, IB levels were as-
sessed in the presence of the proteasomal inhibitor, MG132,
which prevented the stimulus-dependent reduction in IB pro-
tein levels in all of the neuronal cultures (Fig. 7, C and D).
NF-B Activation Is a Central Mediator of Neuroprotec-
tion—To scrutinize the protective role of NF-B from the exci-
totoxic insult of cortical neurons, we blocked NF-B by the use
of three different inhibitors known to interfere with NF-B
activation at distinct levels, i.e. the assembly of the IKK com-
plex via geldanamycin, the blocking of IB phosphorylation
with BAY 11-7082, and the interference with proteasomal deg-
radation of phosphorylated I-B via MG-132 (29–32). Although
MG-132, geldanamycin, and BAY 11-7082 treatment them-
selves showed a slight toxic effect in the in vitro neuronal
culture system, all of these inhibitors completely blocked TNF-
induced protection in TNFR1/ and wild type cortical neu-
rons (Fig. 8, A–C). TNFR2/ neurons served as a negative
control and revealed no influence of the applied inhibitors on
the excitotoxic sensitivity of these cells (Fig. 8, A–C). Likewise,
the resistance of NR2B/TNF-neuronal cultures toward gluta-
mate-induced cell death could be abrogated by pharmacological
intervention with NF-B activation (Fig. 8D). These data pro-
vide strong evidence that NF-B activation and thus transcrip-
tion of NF-B-dependent anti-apoptotic genes play a major role
in TNF-mediated protection of neurons from excitotoxic
insults.
DISCUSSION
We have recently shown the critical involvement of TNF and
its receptors in retinal ischemia in which TNFR1-deficient
animals were protected from ischemic lesions, whereas
TNFR2-deficient animals developed severe pathology and en-
hanced neuronal loss compared with wild type animals. These
data suggested a potential antagonistic function of TNFRs with
respect to neuronal survival upon exogenous stress signals
and/or tissue damage (10). Here we show that the same prin-
ciple applies to cortical neurons and provide evidence for the
underlying mechanism of the protective signal pathway using
an in vitro model of glutamate-induced cell death of primary
cortical neurons. Together, our previous in vivo studies (10)
and the mechanistic in vitro studies presented here provide
compelling evidence for a TNF-mediated anti-apoptotic path-
way via TNFR2. First, a transgenic mouse line (NR2B/TNF)
expressing TNF under the control of the murine NMDAR sub-
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unit NR2B promoter exerts, in vivo, locally restricted modest
TNF activity neither causing brain inflammation nor any ap-
parent pathological signs or neurological deficits.2 Cortical
neurons isolated from these NR2B/TNF mice were signifi-
cantly protected from glutamate-induced apoptosis. Second, we
have used the TNF pretreatment of wild type and TNFR-
deficient primary cortical neurons to mimic the phenotype ob-
served with neurons from TNF transgenic mice and demon-
strate that TNF-treated neurons from wild type and
2 L. Marchetti, M. Klein, K. Schlett, K. Pfizenmaier, and U. L. M.
Eisel, unpublished data.
FIG. 6. Nuclear p65 translocation in primary cortical neurons. A, immunocytochemistry detection of p65 (red fluorescence, Alexa 546) and
III-tubulin (green fluorescence, Alexa 488) in primary cortical wild type (WT) neurons. Left picture shows a TNF-pretreated neuron before
stimulation with glutamate, and the right picture shows a TNF-pretreated neuron after stimulation with glutamate. B, kinetics of TNF-induced
nuclear translocation of p65 (dark gray bars, wild type; black bars, TNFR1/; white bars, TNFR2/). C, kinetics of p65 translocation after TNF
(24 h), MK801 (30 min), or LY294002 (30 min) preincubation and glutamate stimulation as indicated (dark gray bars, wild type; black bars,
TNFR1/; white bars, TNFR2/). D, kinetics of p65 translocation in NR2B/TNF transgenic neurons after MK801 (30 min) or LY294002 (30
min) preincubation and glutamate stimulation as indicated. Nuclear translocation in B, C, and D was quantified by counting within a total of 400
cells/experiment the percentage of neuronal cells with NF-B nuclear staining (as shown in A after treatment with TNF and glutamate). All of the
bars depict the mean  S.D. of three independent experiments, and the distribution of the data sets was analyzed by one-way ANOVA. NF-B
activation in primary cortical neurons. E and F, EMSAs for NF-B activity in primary cortical cultures of different mouse lines. E, nuclear extracts
of WT, TNFR1/, and TNFR2/ neurons after TNF, MK801, or LY294002 preincubation and glutamate stimulation as indicated were incubated
with a 32P-labeled NF-B consensus oligonucleotide and analyzed as described under “Experimental Procedures.” F, nuclear extracts from
NR2B/TNF transgenic neurons after MK801 or LY294002 preincubation and glutamate stimulation as indicated were incubated with a
32P-labeled NF-B consensus oligonucleotide and analyzed as described under “Experimental Procedures.” G, supershift for NF-B. Nuclear
extracts of WT, R1/, R2/, and NR2B/TNF transgenic neurons were preincubated with p65, p50, or cRel antibodies (1 g/ml) and analyzed
as described under “Experimental Procedures.”
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TNFR1/ mice were significantly protected, whereas primary
neurons from TNFR2/ mice were susceptible to cell death.
Third, we show by kinetic analyses of NF-B activation and by
pharmacological inhibition of signal pathway components in
the TNFR knock-out mouse strains that neuroprotection is
mediated via a TNFR2-PI3K-Akt-NF-B pathway in which the
duration of NF-B activation is the critical determinant in
mounting resistance toward excitotoxic insults.
The high concentration of soluble recombinant murine TNF
required to achieve significant protection in vitro is already
indicative of an involvement and critical role of TNFR2, which
has at 37 °C a lower affinity for soluble TNF and a reduced
signal competence as compared with TNFR1, thus necessitat-
ing higher TNF concentrations for signaling (33). Moreover, the
primary neurons derived from the TNF transgenic mouse line
that are protected from excitotoxicity express TNF not only in
its processed form but also at the neuronal cell membrane, a
prerequisite for efficient TNFR2 activation. Both an autotropic
and a juxtatropic signaling of membrane-expressed TNF are
conceivable. As cortical neurons co-express both TNFRs, we
conclude that, under constitutive membrane TNF expression in
the transgenic neurons, the neuroprotective TNFR2 pathway is
dominant over TNFR1 signals. Direct support for differential
roles of the two TNFRs in signaling neuronal survival comes
from the use of TNFR-specific agonistic antibodies where
TNFR2- but not TNFR1-specific agonists promoted protection
from excitotoxicity. A differential role of TNFR1 and TNFR2
has also been reported for hippocampal neurons responding to
TNF alone with TNFR1 inducing both NF-B activation and
cell death, whereas TNFR2 was found to stimulate p38 mito-
gen-activated protein kinase (11). However, this study neither
addressed the functional significance of TNFR2-mediated p38
activation nor resolved the underlying mechanism of apoptosis
dominance in these cells in the presence of an apparently
strong NF-B activation (11), which is considered to play an
important role in neuroprotection (34). As an example, the
FIG. 6—continued
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cellular inhibitors of apoptosis proteins, well known NF-B-
target gene(s) up-regulated by TNF, have been recently iden-
tified as facilitators in down-regulating apoptosis sensitivity
within neurons (35, 36). The prominent role of NF-B in pro-
tection from neurodegeneration has recently received further
support from a transgenic model characterized by forebrain-
specific, inducible, and complete ablation of NF-B activity by
I-B superrepressor (37). Hippocampal slice cultures from
these NF-B-deficient animals presented with strongly in-
creased lesions upon excitotoxic stress.
In accordance with the important role of NF-B in neuropro-
tection, here we show that upon in vitro glutamate exposure of
TNF-treated cortical neurons, a PI3K-dependent PKB/Akt
phosphorylation was ensued by NF-B activation. The kinetics
of both PKB/Akt and NF-B activation support a TNFR2-ini-
tiated signal pathway to NF-B in a PI3K-dependent manner
and the involvement of PKB/Akt. A potential role of other
kinases located downstream of PI3K that could contribute to
NF-B activation in response to TNF, e.g. PKC, cannot be
formally ruled out. However, in vivo, PKC is apparently a
FIG. 7. Western blot analyses of Ib in lysates from primary cortical cultures of different mouse lines treated with glutamate and
inhibitors of PI3K. A, detection of Ib degradation and phosphorylation in primary cortical wild type (WT), TNFR1/ (R1/), and TNFR2/
(R2/) neurons after TNF or LY294002 preincubation and glutamate stimulation as indicated. B, detection of Ib degradation and phosphoryl-
ation in NR2B/TNF transgenic neurons after LY294002 preincubation and glutamate stimulation as indicated. Immunoblotting of the glutamate
receptor 1 protein (GluR1) was performed in order to control equal protein loading for all of the cell lines, because GluR1 levels were constant
during stimulation. C, verification of Ib phosphorylation in the presence of the proteasomal inhibitor MG-132 in primary cortical WT, TNFR1/,
TNFR2/, and neurons after TNF preincubation and glutamate stimulation as indicated. D, verification of Ib phosphorylation in the presence
of the proteasomal inhibitor, MG-132, in primary cortical NR2B/TNF transgenic neurons after glutamate stimulation as indicated. Equal protein
loading for C and D was assessed by GluR1 immunoblotting (data not shown).
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tissue-selective NF-B activator with its dominant function
(with respect to NF-B activation) in lung tissues (39). More-
over, the main action of PKC in the context of TNF-mediated
NF-B activation has now been recognized to be at the level of
RelA transactivation (38). In contrast, our data indicate that
PI3K operates at a level upstream of IB degradation, i.e.
probable at the level of IKK activation or IB itself as shown in
other cell systems (39–43). Examples with established cell
lines show that PKB/Akt may serve as an IKK kinase in re-
sponse to TNF (42). More recent data indicate that IKK is the
prime target of PKB/Akt phosphorylation in the heterotrimeric
IKK complex, resulting in IKK activation and subsequent
IkB phosphorylation (47). Our data with primary neurons
reveal PKB/Akt activation in a TNFR2-specific manner. Strict
PI3K dependence of TNFR2-mediated IB phosphorylation and
activation of p50/p65 as well as neuroprotection is in full agree-
ment with a cell context-specific function of PKB/Akt in the
canonical NF-B pathway.
Of note, NF-B activation via TNFR1-induced pathways did
not protect cortical neurons from glutamate-induced apoptosis,
which is in accordance with data from hippocampal neurons
responding to TNF only (11). Interestingly, our data reveal
that, in primary neurons, TNFR1- and TNFR2-induced path-
ways differ with respect to the kinetics and duration of NF-B
activation with the TNFR1 inducing a rapid but transient
NF-B response and TNFR2 generating a more persistent re-
sponse, still discernible after several hours when stimulated
with TNF alone. As an implication, the duration of NF-B
activation is critical to achieve significant tissue protection.
The usage of different upstream activators of NF-B by TNFR1
and TNFR2 is a probable explanation for the observed differ-
ential kinetics and duration of the NF-B response. Indeed, it
becomes increasingly apparent that the cell-specific quantita-
tive composition with signal proteins contributing to a complex
and multi-regulated pathway critically determines response
phenotypes. For NF-B activation, for example, a multitude of
combinatorial possibilities exist, constituting canonical and
non-canonical pathways, and comprise of several potential up-
stream IKK-activating kinases and several IB isoforms with
differential sensitivity to degradation and feedback regulation
FIG. 8. NF-B activation is important for glutamate resistance. A, TNF-mediated neuroprotection in the absence (open symbols) or
presence of the proteasome inhibitor, MG-132 (filled symbols).  and f, wild type (WT); E and , TNFR1/ (R1/);  and , TNFR2/
(R2/); ‚ and Œ, WT without glutamate to detect possible toxicity of the inhibitor (performed for all of the cell lines shown as an example for wild
type cells). B, TNF-induced resistance against glutamate induced cell death in the absence (open symbols) or presence of the Hsp90 inhibitor,
geldanamycin (filled symbols).  and f, WT; E and , R1/; and, R2/; ‚ and Œ, WT without glutamate to detect possible toxicity of the
inhibitor (performed for all of the cell lines shown as an example for wild type cells). C, TNF-mediated neuroprotection in the absence (open
symbols) or presence of the IB phosphorylation inhibitor, BAY 11-7082 (filled symbols).  and f, WT; E and , R1/; and, R2/; ‚ and
Œ, WT without glutamate to detect possible toxicity of the inhibitor (performed for all of the cell lines shown as an example for wild type cells). D,
glutamate resistance of NR2B/TNF transgenic neurons can be reverted by both MG132 and geldanamycin. ‚, NR2B/TNF; Œ, NR2B/TNF plus
MG-132; , NR2B/TNF plus geldanamycin. Cell death in A, B, C, and D was assessed by MTT assay (n  3) as described under “Experimental
Procedures.”
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(45–48). The individual composition of a cell with the relative
amounts of each of these signaling molecules may not only
influence the potential linkage to receptor proximal signals but
also the kinetics and duration of NF-B activation. Our data
provide a clear example that differences in the initial signal
input (TNFR1 versus TNFR2 pathway), although activating
the same intracellular key molecule (NF-B), are translated
into a completely different signal output (cell death versus
survival) by virtue of a differential duration of the active state
of this critical molecule.
Blocking the NMDA receptor with MK801 lead to a reduction
of PKB/Akt and NF-B activation, revealing an as of yet un-
known cross-talk among a cytokine receptor, TNFR2, and the
ionotropic NMDA receptor. It can be speculated that this pos-
itive cooperation with respect to PKB/Akt and NF-B activa-
tion may serve as a regulative feedback to limit cytotoxic sig-
nals emanating from overactivated NMDARs. In favor of this
reasoning, only persistent NF-B activation is associated with
protection from cell death. Our data show that this requires a
cooperative action of TNFR2 with the ionotropic NMDA recep-
tor, which meet above or at the level of PI3K-PKB/Akt. The
molecular mechanisms of the NMDAR-TNFR2 cooperation are
not yet resolved. It is apparent from sequential stimulation
studies (data not shown) that the signals emanating from
TNFR2 have to precede the excitotoxic insult. At first glance,
this would be in accordance with strictly TNF-mediated acqui-
sition of an apoptosis-resistant state of the cell via an NF-B-
dependent transcriptional response without a contribution of
NMDAR signals. However, pharmacological inhibition of the
PI3K pathway just before glutamate stimulation not only
blocked the TNFR2-dependent and NMDAR-enhanced stimu-
lation of PKB/Akt and NF-B but also fully abrogated protec-
tion from apoptosis. This finding suggests that the acute signal
cross-talk between the two receptor systems is essential for
establishing a protective response. We propose that sustained
PKB/Akt activity ensures prolonged NF-B activity and coun-
terbalances the negative feedback of NF-B-dependent IB
expression typical for TNFR1-mediated signals causing tran-
sient NF-B activity (9). Indeed, neurons protected from exci-
totoxicity showed consistently reduced/lower IkB levels as com-
pared with sensitive ones. In support of our reasoning, a recent
study has linked calcium-induced pathways via PI3K and Akt
toward NF-B activation in neuronal cells (51).
A critical function of other PI3K-PKB/Akt pathways in neu-
ronal survival has been proposed, and several downstream
targets aside from NF-B, in particular Bad, potentially inter-
fere with apoptotic signals and could be involved in neuropro-
tection (49). For example, calcineurin-induced Bad dephospho-
rylation seems to play an important role in calcium-induced
apoptosis within hippocampal neurons, an effect feasible in
glutamate-treated cortical neurons as well (50). However, a
dominant role for other PKB/Akt substrates, including Bad, in
TNF-induced protection of cortical neurons from excitotoxicity
seems unlikely because selective inhibitors of NF-B activation
operating downstream of PKB/Akt, such as a specific inhibitor
of IB phosphorylation (31, 32) or inhibition of proteasomal
IB degradation (30), prevented protection from glutamate-
induced cell death.
TNF is up-regulated in a number of neurodegenerative dis-
orders including Alzheimer’s disease, stroke, and multiple scle-
rosis. However, its function remained to be defined because
both neurotoxic and neuroprotective effects during disease
pathogenesis have been described previously (50–55). The TNF
transgenic mouse line described here clearly shows that re-
stricted neuronal TNF expression is a priori not harmful. To
the contrary, the response phenotype of primary neurons iso-
lated from these mice suggests that TNF expression conditions
the neurons toward resistance to excitotoxic insults. Support
for the in vivo relevance of a TNFR2-mediated neuroprotective
pathway was previously obtained by us in a model of retinal
ischemia (10). We now have preliminary evidence in a model of
cerebral ischemia that NR2B/TNF transgenic mice display
reduced lesions as compared with wild type animals.3
In conclusion, here our data present that TNF mediates
neuroprotection via TNFR2 and that NMDAR co-signaling
provides new mechanistic insights and sheds new light into
the role of TNF in the brain. We propose that TNF functions
as an important regulatory cytokine in the central nervous
system with differential signaling through the two distinct
TNFRs determining its contribution to degenerative and re-
generative processes. Thus, depending on the type and state
of disease, environmental/external factors, cellular composi-
tion of the affected tissue, and intracellular availability of
TNFR signaling components, TNF may function to aggravate
or ameliorate disease. A complete understanding of the dif-
ferential signals that are initiated by TNFR1 and TNFR2 in
neurons and of their cross-talk with other pathways that are
important for neuronal viability is essential in order to derive
therapeutically effective strategies. From our study, we con-
clude that selective triggering of TNFR2 could be a novel
therapeutic strategy in neurodegenerative diseases because
it actively induces an anti-apoptotic state in neurons by co-
operative action with neurotransmitter receptor signals. This
mechanism elucidated here can now be exploited for thera-
peutic gain in combination with or independent of drugs
interfering with apoptotic signal pathways.
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